Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294:433–9.

Article  CAS  PubMed  Google Scholar 

Kupelian PA, Buchsbaum JC, Elshaikh M, Reddy CA, Zippe C, Klein EA. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above. Cancer 2002;95:2302–7.

Article  PubMed  Google Scholar 

Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, et al. Advanced prostate cancer: AUA/ASTRO/SUO guideline PART I. J Urol. 2021;205:14–21.

Article  PubMed  Google Scholar 

National Comprehensive Cancer Network. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.1.2023. © National Comprehensive Cancer Network, Inc. 2022.

Mottet N, Cornford P, van den Berg RCN, Briers E, Eberli D., De Meerleer G, et al. EAU - EANM - ESTRO - ESUR - ISUP - SIOG Guidelines on Prostate Cancer. Arnhem: EAU Guidelines Office; 2023. https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2023_2023-03-27-131655_pdvy.pdf.

Flores-Fraile M-C, Padilla-Fernández BY, Valverde-Martínez S, Marquez-Sanchez M, García-Cenador M-B, Lorenzo-Gómez M-F, et al. The association between prostate-specific antigen velocity (PSAV), value and acceleration, and of the free PSA/total PSA index or ratio, with prostate conditions. J Clin Med. 2020;9:3400.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nini A, Gandaglia G, Fossati N, Suardi N, Cucchiara V, Dell’Oglio P, et al. Patterns of clinical recurrence of node-positive prostate cancer and impact on long-term survival. Eur Urol. 2015;68:777–84.

Article  PubMed  Google Scholar 

Zumsteg ZS, Spratt DE, Romesser PB, Pei X, Zhang Z, Kollmeier M, et al. Anatomical patterns of recurrence following biochemical relapse in the dose escalation era of external beam radiotherapy for prostate cancer. J Urol. 2015;194:1624–30.

Article  PubMed  PubMed Central  Google Scholar 

Artigas C, Diamand R, Shagera QA, Plouznikoff N, Fokoue F, Otte FX, et al. Oligometastatic disease detection with (68)Ga-PSMA-11 PET/CT in Hormone-sensitive Prostate Cancer Patients (HSPC) with biochemical recurrence after radical prostatectomy: predictive factors and clinical impact. Cancers (Basel). 2021;13:4982.

Article  CAS  PubMed  Google Scholar 

Sathianathen NJ, Butaney M, Konety BR. The utility of PET-based imaging for prostate cancer biochemical recurrence: a systematic review and meta-analysis. World J Urol. 2019;37:1239–49.

Article  CAS  PubMed  Google Scholar 

Kane CJ, Amling CL, Johnstone PAS, Pak N, Lance RS, Thrasher JB, et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 2003;61:607–11.

Article  PubMed  Google Scholar 

Herlemann A, Washington SI, Cooperberg M. Health care delivery for metastatic hormone-sensitive prostate cancer across the globe. Eur Urol Focus. 2019;5:155–8.

Article  PubMed  Google Scholar 

Trabulsi EJ, Rumble RB, Jadvar H, Hope T, Pomper M, Turkbey B, et al. Optimum imaging strategies for advanced prostate cancer: ASCO guideline. J Clin Oncol. 2020;38:1963–96.

Article  CAS  PubMed  Google Scholar 

Fanti S, Minozzi S, Castellucci P, Balduzzi S, Herrmann K, Krause BJ, et al. PET/CT with 11C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data. Eur J Nucl Med Mol Imaging. 2016;43:55–69.

Article  CAS  PubMed  Google Scholar 

Einspieler I, Rauscher I, Düwel C, Krönke M, Rischpler C, Habl G, et al. Detection efficacy of hybrid (68)Ga-PSMA ligand PET/CT in prostate cancer patients with biochemical recurrence after primary radiation therapy defined by phoenix criteria. J Nucl Med. 2017;58:1081–87.

Article  CAS  PubMed  Google Scholar 

Berliner C, Tienken M, Frenzel T, Kobayashi Y, Helberg A, Kirchner U, et al. Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [(68)Ga]PSMA I&T and comparison with published data of [(68)Ga]PSMA HBED-CC. Eur J Nucl Med Mol Imaging. 2017;44:670–77.

Article  CAS  PubMed  Google Scholar 

Evangelista L, Zattoni F, Guttilla A, Saladini G, Zattoni F, Colletti PM, et al. Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis. Clin Nucl Med. 2013;38:305–14.

Article  PubMed  Google Scholar 

Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, et al. Sensitivity, specificity, and predictors of positive (68)Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;70:926–37.

Article  PubMed  Google Scholar 

De Visschere PJL, Standaert C, Fütterer JJ, Villeirs GM, Panebianco V, Walz J, et al. A systematic review on the role of imaging in early recurrent prostate cancer. Eur Urol Oncol. 2019;2:47–76.

Article  PubMed  Google Scholar 

De Bari B, Mazzola R, Aiello D, Fersino S, Gregucci F, Alongi P, et al. Could 68-Ga PSMA PET/CT become a new tool in the decision-making strategy of prostate cancer patients with biochemical recurrence of PSA after radical prostatectomy? A preliminary, monocentric series. Radio Med. 2018;123:719–25.

Article  Google Scholar 

Shaikh F, Dupont-Roettger D, Dehmeshki J, Kubassova O, Quraishi MI. Advanced imaging of biochemical recurrent prostate cancer with PET, MRI, and radiomics. Front Oncol. 2020;10:1359.

Article  PubMed  PubMed Central  Google Scholar 

Crawford ED, Koo PJ, Shore N, Slovin SF, Concepcion RS, Freedland SJ, et al. A clinician’s guide to next generation imaging in patients with advanced prostate cancer (RADAR III). J Urol. 2019;201:682–92.

Article  PubMed  Google Scholar 

Kirste S, Kroeze SGC, Henkenberens C, Schmidt-Hegemann NS, Vogel MME, Becker J, et al. Combining (68)Ga-PSMA-PET/CT-directed and elective radiation therapy improves outcome in oligorecurrent prostate cancer: a retrospective multicenter study. Front Oncol. 2021;11:640467.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barwick TD, Castellucci P. Invited commentary: changing landscape of imaging in recurrent prostate cancer. Radiographics 2020;40:727–30.

Article  PubMed  Google Scholar 

Mansbridge M, Chung E, Rhee H. The use of MRI and PET imaging studies for prostate cancer management: brief update, clinical recommendations, and technological limitations. Med Sci (Basel). 2019;7:85.

CAS  PubMed  Google Scholar 

Farolfi A, Hadaschik B, Hamdy FC, Herrmann K, Hofman MS, Murphy DG, et al. Positron emission tomography and whole-body magnetic resonance imaging for metastasis-directed therapy in hormone-sensitive oligometastatic prostate cancer after primary radical treatment: a systematic review. Eur Urol Oncol. 2021;4:714–30.

Article  PubMed  Google Scholar 

van Leeuwen PJ, Emmett L, Ho B, Delprado W, Ting F, Nguyen Q, et al. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer. BJU Int. 2017;119:209–15.

Article  PubMed  Google Scholar 

Giovacchini G, Picchio M, Coradeschi E, Bettinardi V, Gianolli L, Scattoni V, et al. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2010;37:301–9.

Article  PubMed  Google Scholar 

Mapelli P, Incerti E, Ceci F, Castellucci P, Fanti S, Picchio M. 11C- or 18F-Choline PET/CT for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer. J Nucl Med. 2016;57:43s–48s.

Article  CAS  PubMed  Google Scholar 

Chiaravalloti A, Di Biagio D, Tavolozza M, Calabria F, Schillaci O. PET/CT with 18 F-choline after radical prostatectomy in patients with PSA≤ 2 ng/ml. Can PSA velocity and PSA doubling time help in patient selection? Eur J Nucl Med Mol Imaging. 2016;43:1418–24.

Article  CAS  PubMed  Google Scholar 

Andriole GL, Kostakoglu L, Chau A, Duan F, Mahmood U, Mankoff DA, et al. The impact of positron emission tomography with 18F-fluciclovine on the treatment of biochemical recurrence of prostate cancer: results from the LOCATE trial. J Urol. 2019;201:322–31.

Article  PubMed  PubMed Central  Google Scholar 

Nanni C, Zanoni L, Pultrone C, Schiavina R, Brunocilla E, Lodi F, et al. 18 F-FACBC (anti1-amino-3-18 F-fluorocyclobutane-1-carboxylic acid) versus 11 C-choline PET/CT in prostate cancer relapse: results of a prospective trial. Eur J Nucl Med Mol Imaging. 2016;43:1601–10.

Article  CAS  PubMed  Google Scholar 

Ferrari C, Mammucci P, Lavelli V, Pisani AR, Nappi AG, Rubini D, et al. [(18)F]fluciclovine vs. [(18)F]fluorocholine Positron emission tomography/computed tomography: a head-to-head comparison for early detection of biochemical recurrence in prostate cancer patients. Tomography. 2022;8:2709–22.

Article  PubMed  PubMed Central  Google Scholar 

Scarsbrook AF, Bottomley D, Teoh EJ, Bradley KM, Payne H, Afaq A, et al. Effect of 18F-fluciclovine positron emission tomography on the management of patients with recurrence of prostate cancer: results from the FALCON trial. Int J Radiat Oncol Biol Phys. 2020;107:316–24.

Article  PubMed  Google Scholar 

Jani AB, Schreibmann E, Goyal S, Halkar R, Hershatter B, Rossi PJ, et al. 18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial. Lancet 2021;397:1895–904.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bastawrous S, Bhargava P, Behnia F, Djang DS, Haseley DR. Newer PET application with an old tracer: role of 18F-NaF skeletal PET/CT in oncologic practice. Radiographics 2014;34:1295–316.

Article  PubMed  Google Scholar 

Sheikhbahaei S, Jones KM, Werner RA, Salas-Fragomeni RA, Marcus CV, Higuchi T, et al. (18)F-NaF-PET/CT for the detection of bone metastasis in prostate cancer: a meta-analysis of diagnostic accuracy studies. Ann Nucl Med. 2019;33:351–61.

Article  CAS